Most useful if severe FXIII deficiency is suspected (<1% of normal activity). Distinguish between FXIII deficiency and a FXIII inhibitor. Abnormal results should be confirmed with quantitative testing.
Qualitative Solubility Assay
New York DOH Approval Status
Lt. blue (sodium citrate). Refer to Specimen Handling at aruplab.com for hemostasis/thrombosis specimen handling guidelines.
Transfer 2 mL platelet-poor plasma to an ARUP Standard Transport Tube. (Min: 1 mL)
CRITICAL FROZEN. Separate specimens must be submitted when multiple tests are ordered.
Serum. EDTA plasma, clotted or hemolyzed specimens.
Ambient: 4 hours; Refrigerated: Unacceptable; Frozen: 2 weeks
|Factor XIII, 1:1 Mix||Not Applicable|
|Factor XIII, Qualitative||No Lysis within 24 hours|
This is a qualitative screening test; clot lysis only occurs in specimens with severe factor XIII deficiency (less than 1 percent of normal activity). Severe deficiency may be inherited or acquired (typically due to a factor XIII antibody). If clot lysis occurs in the initial testing, then Factor XIII 1:1 Mix will be added where the test is repeated using a 1:1 mix of patient plasma and pooled normal plasma to distinguish between FXIII deficiency and a FXIII inhibitor. Additional charges apply.
False-positive results (lysis) can be caused by heparin (therapy with unfractionated or low molecular weight heparin or contamination from a line), decreased or abnormal fibrinogen, increased fibrinolysis (inherited or acquired fibrinolytic disorders), fibrinolytic drugs, or other factors that affect clot structure or stability.
85291; if reflexed, add 85291
|Component Test Code*||Component Chart Name||LOINC|
|2002818||Factor XIII, 1:1 Mix||3241-7|
|2002915||Factor XIII, Qualitative||3241-7|
- Clot Solubility
- Factor 13
- Fibrin Stabilizing Factor